Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

Aliment Pharmacol Ther 2011; 33: 541–550 Summary Background Crohn’s disease (CD) is associated with impaired health‐related quality of life (HRQoL). Certolizumab pegol, administered either every 2 weeks (q2w) or q4w, maintains efficacy in patients previously failing on the anti‐TNF agent infliximab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2011-03, Vol.33 (5), p.541-550
Hauptverfasser:	Feagan, B. G., Sandborn, W. J., Wolf, D. C., Coteur, G., Purcaru, O., Brabant, Y., Rutgeerts, P. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Certolizumab Pegol Crohn Disease - drug therapy Digestive system Double-Blind Method Drug Resistance Female Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Agents - therapeutic use Humans Immunoglobulin Fab Fragments - therapeutic use Immunologic Factors - therapeutic use Infliximab Male Medical sciences Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Polyethylene Glycols - therapeutic use Quality of Life Severity of Illness Index Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!